BRAF V600E-mutant colorectal cancer

URI: https://gptkb.org/entity/BRAF_V600E-mutant_colorectal_cancer
GPTKB entity
Statements (23)
Predicate Object
gptkbp:instanceOf colorectal cancer subtype
gptkbp:aminoAcidChange valine to glutamic acid at position 600
gptkbp:clinicalTrialPhase BEACON CRC trial
gptkbp:containsGene gptkb:BRAF
gptkbp:FDAApproved encorafenib plus cetuximab
gptkbp:hasDemographicAssociation more common in older women
gptkbp:hasMetastaticPattern peritoneal and distant lymph node metastases
gptkbp:hasMolecularFormula CpG island methylator phenotype
microsatellite instability (in some cases)
gptkbp:hasMutationType missense mutation
gptkbp:hasPrognosticMarker gptkb:BRAF_V600E_mutation
gptkbp:hasResistanceMechanism EGFR pathway activation
gptkbp:hasTherapy BRAF inhibitor
MEK inhibitor
EGFR inhibitor
https://www.w3.org/2000/01/rdf-schema#label BRAF V600E-mutant colorectal cancer
gptkbp:incidence ~1-2% of all colorectal cancers
gptkbp:location right-sided colon
gptkbp:mutationAssociatedWith gptkb:BRAF_V600E
gptkbp:prevalence 8-12% of metastatic colorectal cancers
gptkbp:prognosis poor
gptkbp:bfsParent gptkb:EGFR_inhibitors_(in_colorectal_cancer)
gptkbp:bfsLayer 7